Skip to main content
OpenTrials
Completed

NCT Number: NCT02744430

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography) scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ureteral Obstruction Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Flank Pain Male Urogenital Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Ureteral Diseases Ureterolithiasis Urogenital Diseases Urolithiasis Urologic Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Ben Taub General Hospital

Houston, Texas, 77030, United States

About this study

The study will be a prospective randomized double-blind placebo-controlled trial of mirabegron for medical expulsive therapy (MET) in patients with a CT scan-proven ureteral stone between 4 to 10 mm undergoing expectant management. Subjects will be distributed at a 1:1 ratio between the control and treatment groups. The treatment group will receive mirabegron and the control groups will receive a placebo. Both groups will receive analgesics and hydration will be recommended. All subjects will then be followed for 30 days to determine the proportion of subjects with spontaneous passage. Patients will record narcotic usage and pain scores during this time. If there is stone persistence in the ureter based on imaging (CT scan of the abdomen and pelvis versus renal ultrasound plus KUB), then the patient will undergo ureteroscopy with stent placement. In these patients, treatment will continue while the stent is in place and patients will fill out a validated questionnaire regarding stent pain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter
  • Serum creatinine within normal range
  • Ability to tolerate oral fluids and oral pain medication
  • Able to make informed medical decisions regarding consent
  • Willingness to follow-up in the Urology Clinic in approximately 30 day
  • Willing to undergo ureteroscopic extraction should the stone not pass in this time period

Exclusion criteria

  • Adults unable to consent
  • Age less than 18
  • Multiple stones
  • Solitary kidney
  • Horseshoe kidney
  • On immunosuppressant therapy
  • On digoxin
  • Uncontrolled hypertension (Systolic blood pressure > 170, diastolic blood pressure > 110)
  • History of ureteral surgery or previous endoscopic procedure
  • Allergy to mirabegron
  • Current calcium antagonist or corticosteroid or tamsulosin usage
  • Patients already taking a beta-adrenergic agonist medication
  • Renal insufficiency [Glomerular Filtration Rate (GFR) less than 60]
  • Patients with Childs B and C liver failure
  • Signs of infection i. Temperature greater than 38 degrees Celsius ii. Urinalysis with any of the following positive:
  • Positive nitrites
  • White blood cell count greater than 15/hpf (high powered field)
  • Positive urine culture [defined as a single isolated bacterial species population of greater than 100,000 Colony Forming Units (CFU)]
  • Patients with chronic pain already undergoing treatment with narcotic medications
  • Pregnant women and nursing mothers
  • Prisoners
  • No working phone number

Treatment and study plan

Mirabegron

Drug

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.

Other names: Myrbetriq

Placebo

Other

Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.

Primary outcomes

  1. Spontaneous Stone Passage Using Fisher's Exact Test

    Time frame: 30 days

    The primary outcome was stone passage rate at 30-days defined by either imaging (CT or Renal Ultrasound/KUB) or identification of stone using a straining device.

Secondary outcomes

  1. Comparison of Pain Levels Between Treatment Groups Using the Wong-Baker Pain Rating Scale

    Time frame: 2 months

    Pain measures between treatment groups will be measured daily for each patient by using the Wong-Baker Pain Rating Scale. The Questionnaire will be observed in patients who require surgical intervention, and will be observed during study visit. A general linear model will be used to compare Wong-Baker pain scores between the treated and placebo groups. The model will also be used to explore associations between pain scores and demographic or clinical characteristics adjusting for treatment group.

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Registry information

Official study title

A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02)

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Apr 20, 2016
Registry last updated
Apr 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.